Allogene Therapeutics, Inc(NASDAQ:ALLO) 
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candi...
Website: http://www.allogene.com
Founded: 2017
Full Time Employees: 264
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.33
H 1.46
L 1.32
C 1.44
V 3,588,870
10EMA 1.44
20EMA 1.44
60EMA 1.44
120EMA 1.44
250EMA 1.44